APG-3288 for Blood Cancers That Have Returned or Stopped Responding to Treatment
Tests the drug APG-3288 in adults whose blood cancers returned or resisted treatment.
Key facts
- Who runs it
- Ascentage Pharma Group Inc.
- Where
- East Brunswick, Grand Rapids, Houston, Jacksonville, and Los Angeles, United StatesSee the 5 sitesAlso in 1 other country, 1 site
- Trial code
- Registry title
- A Study of APG-3288 in Relapsed/Refractory Blood Cancers
- Status
- Recruiting
- Phase
- Phase 1
- People taking part
- 180 people, planned
- Started
- 10 Mar 2026
- Expected to end
- Dec 2031
- Type of study
- Interventional, 2 groups
- Treatments tested
- APG-3288
- Record updated
- 15 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose blood cancer has come back or has not responded to earlier treatment. They will take APG-3288 by mouth once a day.
- Age
- 18 years or older.
- Sex
- All sexes can join.
- Disease stage
- Relapsed or refractory CLL/SLL, DLBCL (including Richter transformation), MCL, WM, MZL or FL, confirmed by tissue or cell tests. The disease must be measurable. Activity level (ECOG) must be 1 or lower in Part 1 and 2 or lower in Part 2.
- Earlier treatment
- At least 2 earlier lines of systemic therapy, including a BTK inhibitor where one is approved. People must have failed, or cannot have, other therapies with proven benefit. Earlier BTK degrader treatment or allogeneic stem cell transplant is not allowed.
Main reasons for not taking part
- Other cancer treatment at the same time, or any investigational therapy within 14 days
- Symptomatic brain or spinal cord involvement by the cancer
- Serious heart disease, such as class III or IV heart failure or a recent heart attack
- Active uncontrolled infection or autoimmune disease
- Treatment doses of blood thinners, or another cancer apart from a few exceptions
The registry criteria, word for word
Show all 19 criteriaShow less
Who can take part
- Eastern Cooperative Oncology Group (ECOG) status ≤ 1 in Part 1 (dose escalation), and ≤ 2 in Part 2 (dose expansion)
- Part 1 (Dose Escalation): histologically or cytologically confirmed diagnosis of R/R CLL/SLL, DLBCL (including Richter Transformation), MCL, WM, MZL, or FL
- Prior systemic therapy: at least 2 prior lines of systemic therapy (including BTK inhibitor for approved indications) and who have failed or are not eligible for available therapies with established clinical benefit
- Measurable disease per response criteria specific to the malignant condition
- Adequate organ and bone marrow function
Who cannot take part
- Any investigational therapy within 14 days prior to the first dose of study drug or within 5 half-lives of the respective investigational drug (whichever is shorter)
- Persistent toxicities from prior radiotherapy, targeted therapy, immunotherapy, or chemotherapy agents that have not recovered to Grade <2 (except for alopecia or vitiligo)
- Symptomatic brain metastases due to tumor involvement of the central nervous system (CNS). Patients with CNS tumors who have been treated, are asymptomatic, and who have discontinued steroids (for the treatment of CNS tumors) for > 28 days may be enrolled
- Biological growth factors within 7 days prior to the first dose of study drug
- Patients who, in the investigator's judgment, have not adequately recovered from prior surgery, or have undergone major surgery within 28 days prior to enrollment, or minor surgery within 14 days prior to enrollment
- Concurrent malignancy other than the one being treated in this study with the exception of the following: cured malignancy without recurrence within 3 years prior to study entry; completely resected basal cell and squamous cell skin cancer; completely resected carcinoma in situ of any type
- Prior treatment with: BTK degrader treatment or allogeneic stem cell transplant
- Clinically active and uncontrolled symptomatic infection; well-controlled human immunodeficiency virus (HIV), hepatitis B virus (HBV), or hepatitis C virus (HCV) infection may be considered for enrollment
- Autoimmune diseases, active inflammatory bowel disease, chronic infections, or any other disease or condition associated with chronic inflammation
- Any severe and/or uncontrolled medical condition that, in the investigator's opinion, may compromise the individual's safety or the evaluation of study results
- Concurrent anti-cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, hormonal therapy, targeted therapy, biologic therapy, with the exception of hormones for hypothyroidism or estrogen replacement therapy, anti-estrogen analogs, agonists required to suppress serum testosterone levels)
- Significant cardiac disease defined as:; New York Heart Association class III or IV cardiac disease, including pre-existing uncontrolled, clinically-significant arrhythmia, congestive heart failure, or cardiomyopathy; Unstable angina, myocardial infarction, or a coronary revascularization procedure within ≤ 3 months prior to initiation of study treatment; History of left ventricular ejection fraction < 50%; Poorly controlled hypertension, or history of poor compliance with antihypertensive drug regimens
- Concurrent use of QT-prolonging medications or history of torsades de pointes
- Use of therapeutic-dose anticoagulants or antiplatelet agents. (Use of low-dose anticoagulants to maintain central venous catheter patency is permitted)
Where in United States
Also in 1 other country, 1 site
- START - New JerseyEast Brunswick, United StatesContact: Yifan Zhai, M.D., Ph.D.Taking people
- START | MidwestGrand Rapids, United StatesContact: Yifan Zhai, M.D., Ph.D.Taking people
- The University of TX MD Anderson Cancer CenterHouston, United StatesContact: Yifan Zhai, M.D., Ph.D.Not yet recruiting
- Mayo ClinicJacksonville, United StatesContact: Yifan Zhai, M.D., Ph.D.Taking people
- START Los AngeleLos Angeles, United StatesContact: Yifan Zhai, M.D., Ph.D.Taking people
About the trial
What the trial wants to find out
This is a Phase I, multicenter, open-label, two-stage study of APG-3288 monotherapy, aiming to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of APG-3288 administered orally once daily in patients with relapsed/refractory (R/R) hematologic malignancies.
The 2 groups in the trial
- Part 1 (Dose Escalation Phase)Treatment being tested
APG-3288 at multiple dose levels will be evaluated to determine the recommended phase 2 dose (RP2D) or maximum tolerated dose (MTD).
Treatment: APG-3288
- Part 2 (Dose Expansion Phase)Treatment being tested
Indications and dose cohorts to be determined from Part 1
Treatment: APG-3288
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Phase I Study to Evaluate the Safety, Pharmacokinetics, and Preliminary Efficacy of APG-3288 in Patients With Relapsed/Refractory Hematological Malignancies
- Plain-language title
- APG-3288 for Blood Cancers That Have Returned or Stopped Responding to TreatmentGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 13 November 2026.
- Record updated
- 15 October 2026